Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 180

1.

Enhancing cellular uptake of activable cell-penetrating peptide-doxorubicin conjugate by enzymatic cleavage.

Shi NQ, Gao W, Xiang B, Qi XR.

Int J Nanomedicine. 2012;7:1613-21. doi: 10.2147/IJN.S30104. Epub 2012 Mar 26.

2.

Tumor targeting of MMP-2/9 activatable cell-penetrating imaging probes is caused by tumor-independent activation.

van Duijnhoven SM, Robillard MS, Nicolay K, Grüll H.

J Nucl Med. 2011 Feb;52(2):279-86. doi: 10.2967/jnumed.110.082503. Epub 2011 Jan 13.

3.

PEGylated liposomes with NGR ligand and heat-activable cell-penetrating peptide-doxorubicin conjugate for tumor-specific therapy.

Yang Y, Yang Y, Xie X, Cai X, Zhang H, Gong W, Wang Z, Mei X.

Biomaterials. 2014 May;35(14):4368-81. doi: 10.1016/j.biomaterials.2014.01.076. Epub 2014 Feb 22.

PMID:
24565519
4.

Protease-Activable Cell-Penetrating Peptide-Protoporphyrin Conjugate for Targeted Photodynamic Therapy in Vivo.

Li SY, Cheng H, Qiu WX, Liu LH, Chen S, Hu Y, Xie BR, Li B, Zhang XZ.

ACS Appl Mater Interfaces. 2015 Dec 30;7(51):28319-29. doi: 10.1021/acsami.5b08637. Epub 2015 Dec 17.

PMID:
26634784
5.

Activable Cell-Penetrating Peptide Conjugated Prodrug for Tumor Targeted Drug Delivery.

Cheng H, Zhu JY, Xu XD, Qiu WX, Lei Q, Han K, Cheng YJ, Zhang XZ.

ACS Appl Mater Interfaces. 2015 Jul 29;7(29):16061-9. doi: 10.1021/acsami.5b04517. Epub 2015 Jul 20.

PMID:
26161578
6.

In vivo biodistribution of radiolabeled MMP-2/9 activatable cell-penetrating peptide probes in tumor-bearing mice.

van Duijnhoven SM, Robillard MS, Nicolay K, Grüll H.

Contrast Media Mol Imaging. 2015 Jan-Feb;10(1):59-66. doi: 10.1002/cmmi.1605. Epub 2014 May 13.

PMID:
24823643
7.

Metalloprotease-specific poly(ethylene glycol) methyl ether-peptide-doxorubicin conjugate for targeting anticancer drug delivery based on angiogenesis.

Bae M, Cho S, Song J, Lee GY, Kim K, Yang J, Cho K, Kim SY, Byun Y.

Drugs Exp Clin Res. 2003;29(1):15-23.

PMID:
12866360
8.

Imaging of MMP activity in postischemic cardiac remodeling using radiolabeled MMP-2/9 activatable peptide probes.

van Duijnhoven SM, Robillard MS, Hermann S, Kuhlmann MT, Schäfers M, Nicolay K, Grüll H.

Mol Pharm. 2014 May 5;11(5):1415-23. doi: 10.1021/mp400569k. Epub 2014 Apr 9.

PMID:
24641497
9.

A doxorubicin-CNGRC-peptide conjugate with prodrug properties.

van Hensbergen Y, Broxterman HJ, Elderkamp YW, Lankelma J, Beers JC, Heijn M, Boven E, Hoekman K, Pinedo HM.

Biochem Pharmacol. 2002 Mar 1;63(5):897-908.

PMID:
11911842
10.

Cell-penetrating peptide-doxorubicin conjugate loaded NGR-modified nanobubbles for ultrasound triggered drug delivery.

Lin W, Xie X, Deng J, Liu H, Chen Y, Fu X, Liu H, Yang Y.

J Drug Target. 2016;24(2):134-46. doi: 10.3109/1061186X.2015.1058802. Epub 2015 Jul 15.

PMID:
26176270
11.

MMPs-specific PEGylated peptide-DOX conjugate micelles that can contain free doxorubicin.

Lee GY, Park K, Kim SY, Byun Y.

Eur J Pharm Biopharm. 2007 Nov;67(3):646-54. Epub 2007 Apr 2.

PMID:
17499491
12.

Chemotherapeutic drug delivery to cancer cells using a combination of folate targeting and tumor microenvironment-sensitive polypeptides.

Gao W, Xiang B, Meng TT, Liu F, Qi XR.

Biomaterials. 2013 May;34(16):4137-49. doi: 10.1016/j.biomaterials.2013.02.014. Epub 2013 Mar 1.

PMID:
23453200
13.

Tumor-targeting and microenvironment-responsive smart nanoparticles for combination therapy of antiangiogenesis and apoptosis.

Huang S, Shao K, Liu Y, Kuang Y, Li J, An S, Guo Y, Ma H, Jiang C.

ACS Nano. 2013 Mar 26;7(3):2860-71. doi: 10.1021/nn400548g. Epub 2013 Mar 12.

PMID:
23451830
14.

[The design and enzymatic hydrolysis of activatable cell-penetrating peptide].

Wang PC, Qi XR.

Yao Xue Xue Bao. 2010 Aug;45(8):1048-51. Chinese.

PMID:
21351594
16.

Comparative studies of polyethylenimine-doxorubicin conjugates with pH-sensitive and pH-insensitive linkers.

Dong DW, Tong SW, Qi XR.

J Biomed Mater Res A. 2013 May;101(5):1336-44. doi: 10.1002/jbm.a.34450. Epub 2012 Oct 15.

PMID:
23065848
17.

Biological evaluation of a novel doxorubicin-peptide conjugate for targeted delivery to EGF receptor-overexpressing tumor cells.

Ai S, Duan J, Liu X, Bock S, Tian Y, Huang Z.

Mol Pharm. 2011 Apr 4;8(2):375-86. doi: 10.1021/mp100243j. Epub 2011 Feb 2.

PMID:
21241067
18.

Cytotoxic activity of a tumor protease-activated pore-forming toxin.

Potrich C, Tomazzolli R, Dalla Serra M, Anderluh G, Malovrh P, Macek P, Menestrina G, Tejuca M.

Bioconjug Chem. 2005 Mar-Apr;16(2):369-76.

PMID:
15769091
19.

A smart tumor targeting peptide-drug conjugate, pHLIP-SS-DOX: synthesis and cellular uptake on MCF-7 and MCF-7/Adr cells.

Song Q, Chuan X, Chen B, He B, Zhang H, Dai W, Wang X, Zhang Q.

Drug Deliv. 2016 Jun;23(5):1734-46. doi: 10.3109/10717544.2015.1028601. Epub 2015 Apr 8.

PMID:
25853477
20.

Matrix metalloproteinase-activated doxorubicin prodrugs inhibit HT1080 xenograft growth better than doxorubicin with less toxicity.

Albright CF, Graciani N, Han W, Yue E, Stein R, Lai Z, Diamond M, Dowling R, Grimminger L, Zhang SY, Behrens D, Musselman A, Bruckner R, Zhang M, Jiang X, Hu D, Higley A, Dimeo S, Rafalski M, Mandlekar S, Car B, Yeleswaram S, Stern A, Copeland RA, Combs A, Seitz SP, Trainor GL, Taub R, Huang P, Oliff A.

Mol Cancer Ther. 2005 May;4(5):751-60.

Supplemental Content

Support Center